Octagon Capital Advisors

Octagon Capital Advisors is a New York-based investment firm with a singular focus on the global healthcare sector. The firm distinguishes itself through a comprehensive investment strategy that spans both public and private companies, demonstrating flexibility across the capital structure, including equity, debt, and structured solutions. Octagon positions itself as a long-term partner, aiming to collaborate with management teams to foster the growth and sustainability of their portfolio companies. Their expertise covers the entire lifecycle of a company, from early-stage growth ventures to established, mature public entities.

The firm's investment philosophy is deeply rooted in a thorough understanding of the healthcare industry, leveraging its team's extensive experience in healthcare investing, mergers and acquisitions, and operational management. This deep sector knowledge allows Octagon to identify and support innovative companies poised for significant impact within the complex healthcare landscape. While they engage in private investments, a notable portion of their publicly disclosed portfolio comprises public companies, indicating a strong capability and inclination towards public market participation, including strategic investments in publicly traded healthcare firms.

For its private investments, Octagon Capital Advisors typically targets companies requiring substantial capital for growth and development. For instance, the firm participated in the Series A funding round for Aura Biosciences, which raised $30 million, and subsequently in its $40 million Series B round. These examples suggest that Octagon is comfortable deploying significant capital, often contributing multi-million dollar checks to support promising healthcare innovations. Based on their participation in such substantial funding rounds and their focus on later-stage private and public companies, Octagon Capital Advisors' initial investment checks likely range from approximately $5 million for significant minority stakes in growth-stage companies, extending up to $50 million or more for lead positions in larger private rounds or substantial public market investments. This broad range reflects their adaptable approach to capital deployment across the diverse healthcare ecosystem.